pandas/pans child and adolescent psychopharmacology …-+pandas.pdf · • design: double blind,...
Post on 09-Aug-2019
221 Views
Preview:
TRANSCRIPT
www.mghcme.org
PANDAS/PANSChild and Adolescent Psychopharmacology
March 16, 2019
Barbara J. Coffey, MD, MSDivision Chief, Child and Adolescent Psychiatry
Department of Psychiatry and Behavioral Sciences University of Miami Miller School of Medicine
Director, Uhealth Tics, OCD and Related Problems Program
Professor, Department of Psychiatry
www.mghcme.org
Disclosures (Past 12 Months)
• Abide Therapeutics: Scientific Advisory Board• American Academy of Child and Adolescent Psychiatry: Honoraria• Bracket: Honoraria• Cincinnati Children’s Hospital: Honorarium• Harvard Medical School: Honoraria• Neurocrine Biosciences: Research Support• Nevada Psychiatric Association: Honorarium• NIMH: Research Support• Partners Healthcare: Honoraria• Teva/Nuvelution: Research Support; Scientific Advisory Board• Tourette Association of America: Co-Chair, Medical Advisory Board; TAA-
CDC Partnership
• Off label indications will be discussed
www.mghcme.org
PANDAS/PANS
Learning Objectives
• At the end of this session, the participant should be able to:
• Review diagnostic criteria for Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus (PANDAS) and Pediatric Acute Onset Neuropsychiatric Syndrome (PANS)
• Discuss current controversies in scientific understanding of these disorders
• Recognize clinical presentation of children who may meet diagnostic criteria for PANDAS and PANS
• Consider treatment implications?
www.mghcme.org
Swedo, PANDAS: A “Controversial” Diagnosis
ALL CHILDHOOD-ONSET OCD & TIC DISORDERS
PANDAS
PITANDS
PANS
www.mghcme.org5
Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus (PANDAS): Diagnostic Features (Swedo, S. Leonard, H. et al; Am J Psych 1998; 155; 2; 264-271)
• OCD and/or a tic disorder (lifetime)• Pre-pubertal onset (age 3-12)• Episodic course; abrupt, dramatic or explosive onset or
exacerbation of symptoms• Temporal association of symptom onset or exacerbation with
Group A Beta hemolytic streptococcus (GABHS) by positive throat culture and/or elevated anti-streptococcal antibody titers
• Neurological abnormalities: choreiform and adventitious movements; motoric hyperactivity
www.mghcme.org
www.mghcme.org
Evidence For PANDAS: Antibiotic Studies (Snider, Lougee, Slattery, Grant and Swedo; Biol Psych 2005; 57;
788-792)
• Design: Double blind, randomized controlled trial of antibiotic prophylaxis
• Methods: 23 subjects with PANDAS enrolled. Prophylaxis with penicillin or azithromycin administered for 12 months
• Rates of strep infections and neuropsychiatric symptoms were compared between baseline year and over study year
• Results: Significant decreases in strep infections occurred during the study year: mean 0.1 per subject vs. baseline 1.9 in penicillin group, and 2.4 in azithromycin group (p<0.01).
• Significant decreases in tics/OCD during study year with mean 0.5 per subject in penicillin group and 0.8 in azithromycin group compared to baseline 2.0 in penicillin group and 1.8 in azithromycin group. (p<0.01).
• Conclusion: Both antibiotics were effective in decreasing strep infections and neuropsychiatric symptom exacerbations in PANDAS.
www.mghcme.org
Evidence for PANDAS:Association Between Streptococcal Infection and OCD, Tourette Syndrome (TS),
and Tic DisorderMell, L. Davis, R. Owens, R. Pediatrics 2005;116;56 DOI: 10.1542/peds.2004-2058
• Objective: Large West-Coast HMO assessment whether streptococcalinfection was associated with increased risk for OCD, TS, or tic disorder.
• Methods: Case-control study children age 4-13 with first diagnosis of OCD,TS, or tic disorder between 12/92-12/99.
• Cases matched to controls by birth date, gender, primary physician, andpropensity to seek health care.
• Results: Cases more likely than controls to have had prior streptococcalinfection (OR: 2.22; 95% CI: 1.05, 4.69) in 3 months before onset date. Riskwas higher in children with multiple streptococcal infections within 12months (OR: 3.10; 95% CI: 1.77, 8.96). Having multiple infections with GASwithin a 12- month period was associated with very high increased risk forTS (OR: 13.6; 95% CI: 1.93, 51.0)
• Conclusion: PANDAS may result from a post-infectious autoimmunephenomenon induced by childhood streptococcal infection
www.mghcme.org
Evidence Against PANDAS(Kurlan, R. and Kaplan, E.; Pediatrics; 2004: 113; 883-886)
• GABHS infection is very common in the school age period
• Rates of asymptomatic carriers are high
• Tics and OCD worsen during times of stress and can be worsened by otherprecipitants (fatigue, anxiety, etc.)
• For SC, choreoathetoid movements appear 3-5 months after GABHS;Swedo et al initially suggested infection up to 9 months before symptomonset may be acceptable for PANDAS diagnosis
• Variety of infectious agents have been implicated, ie Borrelia,mycoplasma, common cold.
• Most non-PANDAS TD patients have onset before puberty
• Clinical course: 53% of one series of 80 consecutively referred TS patientshad sudden, explosive worsening or onset of tics (Singer; Ped Neurol,2002)
www.mghcme.org
Streptococcal Infection and Exacerbations of Childhood Tics and Obsessive Compulsive Symptoms: A Prospective Blinded Cohort Study
(Kurlan R, Johnson D, Kaplan E, Tourette Ssyndrome Study Group. Pediatrics. 2008;121:1188-1197)
Streptococcal Upper Respiratory Tract Infections and
Exacerbations of Tic and Obsessive-Compulsive
Symptoms: A Prospective Longitudinal Study.
(Leckman, J. King, R. Gilbert, D. Coffey, B. et al. Journal of the
American Academy of Child and Adolescent Psychiatry;
2011; Volume 50; (2); 108-118).
www.mghcme.org
Summary: PANDAS Prospective Studies
(Kurlan, R. et al 2008; Leckman, J. et al 2011)
1) Streptococcus is a relatively weak, and not particularly unique, precipitant of tic and OCD exacerbations.
2) Conventional treatment of tics and OCD is recommended in children with PANDAS if symptoms cause distress or impairment
3) Antibiotic treatment of acute streptococcal infections is indicated, but prophylaxis is generally not recommended
4) NIMH Work group proposed new criteria (PANS)
www.mghcme.org
Hierarchy of PANS; (Swedo, S. et al. Pediatr Therapeut 2012;
2:2. 1000113)
www.mghcme.org
Diagnostic Criteria Proposed for Pediatric Acute-onset
Neuropsychiatric Syndrome (PANS) (Swedo, S. et al 2012)
Criterion Description
I Abrupt, dramatic onset of obsessive-compulsive disorder or severely
restricted food intake
II Concurrent presence of additional neuropsychiatric symptoms, with similarly
severe and acute onset, from at least two of the following seven categories:
1. Anxiety
2. Emotional lability and/or depression
3. Irritability, aggression and/or severely oppositional behaviors
4. Behavioral (developmental) regression
5. Deterioration in school performance
6. Sensory or motor abnormalities
7. Somatic signs and symptoms, including sleep disturbances, enuresis or
urinary frequency
III Symptoms are not better explained by a known neurologic or medical
disorder, such as Sydenham chorea, systemic lupus erythematosus,
Tourette’s disorder or others.
Note: The diagnostic work-up of patients suspected of PANS must be
comprehensive enough to rule out these and other relevant disorders. The
nature of the co-occurring symptoms will dictate the necessary assessments,
which may include MRI scan, lumbar puncture, electroencephalogram or
other diagnostic tests.
www.mghcme.org
Characterization of the PANS Phenotype(Murphy, T. et al. JCAP; 2015; 14-25)
Objective: PANS is a sub-type of OCD with abrupt onset or exacerbation of neuropsychiatric symptoms. Aim was to characterize presentation.
Methods: N=43 youth ages 4-14 who met criteria for PANS underwent comprehensive psychiatric evaluation.
Results: Youth with PANS had early age of onset (mean=7.84 years) and had moderate to severe OCD symptoms. All had comorbid anxiety and emotional lability, and reduced quality of life.
Youth with PANS and comorbid tics were more likely to have: school performance decline, visual-motor impairment, food restriction, hand writing deterioration and poorer quality of life vs. those without tics.
Conclusion: Findings are suggestive that PANS subgroup consists of sudden onset, severely impaired youth.
www.mghcme.org
Murphy, T. et al 2015
www.mghcme.org
Clinical Evaluation of Youth with PANS: Recommendations from 2013
Consensus Conference. Chang, K. et al. 2015; JCAP; 25 (1); 3-13
www.mghcme.org
Clinical Evaluation of Youth with PANS:
Recommendations from the 2013 Consensus
Conference. Chang, K. et al. 2015; JCAP; 25
(1); 3-13
www.mghcme.org
Clinical Evaluation of Youth with PANS: Recommendations from
the 2013 Consensus Conference. Chang, K. et al. JCAP;
DOI:10.1089/cap.2014.0084
www.mghcme.org
Considerations for PANDAS/PANS Diagnostic Evaluation Professor, Department of Psychiatry
OCD: Abrupt, dramatic, explosive, 24-48 hour onset or exacerbation of symptoms
General Evaluation:
Comprehensive psychiatric evaluation
Physical examination
Examination for choreiform (piano playing finger) movements
Laboratory workup:
48 hour plated throat culture (vs. rapid strep only)
CBC, ESR, CRP, Urinalysis
ASOT and Anti DNAse B
Mycoplasma and Borrelia (Lyme Disease) titers
ANA
EKG
www.mghcme.org
General Principles for Treating Pediatric Acute-Onset Neuropsychiatric Syndrome.
(Swedo, S. et al.; JCAP; 27, (7), 2017; 562-565)
1. Establish PANS is correct ‘‘diagnosis of exclusion’’ by completing a comprehensive diagnostic evaluation (Chang et al. 2015).2. Provide symptomatic relief with psychiatric medications and behavioral interventions, prioritizing treatment of symptoms causing the greatest distress and interference (Thienemann et al. 2017).3. Treat underlying infections and consider use of therapeutic or prophylactic antibiotics (Cooperstock et al. 2017).4. Treat symptoms resulting from neuroinflammation or postinfectiousautoimmunity with anti-inflammatory or immunomodulatory therapies, chosen on the basis of symptom severity and disease trajectory (Frankovich et al. 2017).5. Evaluate effectiveness of treatment at frequent intervals, making modifications as warranted by improvement or worsening of symptoms.6. Treatment can be tapered or stopped when symptoms resolve. However, treatment may be necessary again at some point in the future, given the relapsing–remitting nature of PANS symptoms……
www.mghcme.org
Treatment of Non-Streptococcal PANS (Swedo, S. et al.; JCAP; 27, (7), 2017; 562-565)
1. Long-term antibiotic prophylaxis against streptococcal infections is not recommended
2. Children with PANS often experience exacerbation of neuropsychiatric symptoms during intercurrent sinusitis or other non-streptococcal infections. These should be promptly evaluated and managed according to current standards of practice.
3. It is possible that GAS may initiate a symptom flare in children with non-streptococcal PANS. It is important to be vigilant for possible GAS infection in both the patient and close family members.
4. If the PANS patient or close contact has a sore throat, a throat swab should be obtained and treated promptly if GAS is identified.
5. If the PANS patient has a definite increase in PANS symptoms, careful physical evaluation for an inciting infection should be performed. Skin infection, including perianal dermatitis, would warrant appropriate cultures. A throat swab for GAS should be performed even in the absence of clinical pharyngitis. GAS serology (ASO and ADB), and a polymerase chain reaction test for Mycoplasma pneumoniae may be performed as well.
Mount Sinai / Presentation Slide / December 5, 2012
21
www.mghcme.org22
PANS Treatment: Psychotropics and
Immunomodulation
(T. Murphy, M.D. AACAP, 10.25.13)
Psychotropic medications may exert neuropsychiatric effects via immunomodulation and support of neurogenesis
These agents have been found to have anti-inflammatory effects through suppression of pro-inflammatory cytokines (ie. IL-2, TNF-a, T cell proliferation, etc.)
Some were originally used as antimicrobialsAmoxicillin-clavulanate (Augmentin) is a B-lactamase inhibitor. CNS effects: readily crosses the blood brain barrier and has demonstrated anxiolytic properties in animal models, possibly due to glutamate transmission effects
CNS effects: Promote expression of glutamate transporterNeuroprotective role in vivo and in vitro (Rothstein et al Nature; 2005)
Beta-lactams: penicillin, cephalosporins
www.mghcme.org
Cefdinir for Recent-Onset Pediatric Neuropsychiatric Disorders:
A Pilot Randomized Trial
(Murphy, T. et al JCAP 25 (1) 2015; 57–64; DOI:
10.1089/cap.2014.0010)
Methods:
20 children ages 4-13 with new onset of OCD/tics
– Did not require infectious trigger
– Dosed at 14mg/kg (max 600mg)/day with target length of RCT of 30 days
– Chosen for palatability, safety and efficacy for Group A Streptococcus
– Placebo matched for taste, color, consistency
www.mghcme.org
Cefdinir for Recent-Onset Pediatric Neuropsychiatric Disorders:A Pilot Randomized Trial
(Murphy, T. et al JCAP 25 (1) 2015; 57–64; DOI: 10.1089/2014.0010)
Tanya Murphy, MD
3/8/2019
DemographicsALL
(N=20)PLACEBO (N=11) ANTIBIOTIC (N=9)
Age 7.3±1.9 7.4±1.9 7.2±2.0
Gender F 5 (25.0%)
M 15 (75.0%)
F 4 (36.4%)
M 7 (63.6%)
F 1 (11.1%)
M 8 (88.9%)
Diagnosis %
OCD 20%(n=4) 27% (N=3) 11.1% (N=1)
OCD/Tics 55% (n= 11) 55% (N=6) 56.6% (N=5)
Tics 25% (n=5) 18% (N=2) 33.3% (n=3)
www.mghcme.org
Cefdinir for Recent-Onset Pediatric Neuropsychiatric Disorders:A Pilot Randomized Trial
(Murphy, T. et al JCAP 25 (1) 2015; 57–64; DOI: 10.1089/2014.0010)
TriggerALL
(N=20)
PLACEBO
(N=11)
ANTIBIOTIC
(N=9)
Infectious trigger 14 6 8
Recent URI 8 3 5
Positive GAS (culture/rapid strep)
6 3 3
No evidence of infectious trigger
6 5 1
www.mghcme.org
Cefdinir for Recent-Onset Pediatric Neuropsychiatric Disorders:
A Pilot Randomized Trial
(Murphy, T. et al JCAP 25 (1) 2015; 57–64; DOI: 10.1089/2014.0010
Mean CYBOCS Scores
www.mghcme.org
Cefdinir for Recent-Onset Pediatric Neuropsychiatric Disorders:
A Pilot Randomized Trial
(Murphy, T. et al JCAP 25 (1) 2015; 57–64; DOI: 10.1089/2014.0010
Mean CYBOCS Scores
YGTSS PLACEBO VS. CEFDINIR SCORE CHANGE
www.mghcme.org
Cefdinir for Recent-Onset Pediatric Neuropsychiatric Disorders:A Pilot Randomized Trial
(Murphy, T. et al JCAP 25 (1) 2015; 57–64; DOI: 10.1089/2014.0010.
Results: Tics: subjects on cefdinir had improvement in tic symptoms; 44.4% at least a
25% reduction in YGTSS (mean decrease = 9.5) scores vs. 9.1 placebo group (mean
decrease = 0.13).
No significant group differences for YGTSS (F [1, 13] = 4.03, p = 0.066)
OCD: subjects on cefdinir had improvement in OCD symptoms; 33.3% at least a 25%
reduction in CY-BOCS scores (mean decrease = 7.8)vs. 27.3% placebo group (mean
decrease = 4.7)
No significant differences CY-BOCS (F [1, 13] = 0.385, p = 0.546; d = 0.24).
Conclusion: Subjects on cefdinir had non-statistically significant improvement in tic
symptoms, vs.placebo group. There were some improvements in OCD symptoms,
although not significant.
Overall, cefdinir was well tolerated. Given preliminary results, a fully powered study is
warranted to explore efficacy of cefdinir as a therapeutic tool for new-onset pediatric
neuropsychiatric symptoms, particularly those
that appear to be precipitated by infection.
www.mghcme.org
Randomized, Controlled Trial of IntravenousImmunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated
With Streptococcal Infections
(Williams, K. et al. J Am Acad Child Adolesc Psychiatry 2016; 55(10):860–867).
Method: N= 35 children meeting criteria for PANDAS and moderate to severe
obsessive-compulsive disorder (OCD)
6-week trial of IVIG (1g/kg/day on 2 consecutive days), followed by optional
open-label treatment for non-responders, with follow-up at
12 and 24 weeks.
Primary outcome measures were CYBOCS and (CGI-I) rating. “
Responders” were defined, a priori, by a 30% decrease in CY-BOCS total
score, and a “much” or “very much” improved rating on CGI-I.
www.mghcme.org
Randomized, Controlled Trial of IVIG for Pediatric Autoimmune Neuropsychiatric Disorders Associated With
Streptococcal Infections (Williams, K. et al. J Am Acad Child Adolesc Psychiatry 2016;55(10):860–867).
• Results: DB: mean decrease in CY-BOCS score 24% (+- 31%) in the IVIG group and 12%(+- 27%) in the placebo group; 6 responders in IVIG group (35%)vs 4 (22%) in placebo group; not statistically significant.
• 24 participants met criteria for nonresponse to double-blind and received open-label IVIG at week 6. Among allparticipants, mean C-BOCS improvement frombaseline was 55%(+-33%) at week 12 and 62%(+- 33%) atweek 24.Conclusion: IVIG was safe and well tolerated. Between group differences weresmaller than anticipated, and DB comparison failed to demonstrate superiorityof IVIG over placebo.
www.mghcme.org
Randomized, Controlled Trial of IVIG for Pediatric Autoimmune Neuropsychiatric Disorders Associated With
Streptococcal Infections (Williams, K. et al. J Am Acad Child Adolesc Psychiatry 2016;55(10):860–867).
www.mghcme.org
EMTICS PANDAS/PANS Study Results (Hoekstra, P. et al. February 2019)
• EMTICS: a longitudinal observational European multicentre study involving 16 clinical centres with following objectives:
• to investigate association of environmental factors (GAS exposure and psychosocial stress primarily) with the onset and course of tics and/or obsessive–compulsive symptoms through the prospective observation of at-risk individuals (ONSET cohort: 260 children aged 3–10 years who are tic-free at study entry and have a first-degree relative with a chronic tic disorder)
• and affected individuals (COURSE cohort: 715 youth aged 3–16 years with a tic disorder)
www.mghcme.org
EMTICS PANDAS/PANS Study Results; February 2019
• The most significant result from the cohort studies is that we found no indication for a role of new GAS exposures in relation to exacerbations of tic disorders.
• We did find that new GAS exposures are very frequently occurring.
• Our data indicate that exposure to GAS at some point during childhood is nearly universal.
• Thus, it is quite understandable that a part of the children who come to clinics with a tic exacerbation have signs of a recent GAS exposure. Clinical observations of the co-occurrence of recent GAS exposures and tic exacerbation have led to the PANDAS concept.
• However, the EMTICS study indicates that the co-occurrence of tic exacerbations and recent new GAS exposures is most likely due to chance. …”
www.mghcme.org34
PANDAS and PANS: Summary: What is GCP for
CAPs?
1. Comprehensive evaluation of children with acute onset OCD/tic symptoms is essential.
2. Some may have infectious, autoimmune or stress related precipitants, but at this time evidence is lacking for specific clinical or biological markers. The prevalence of these children is likely very low.
3. Children with acute, abrupt or explosive onset or exacerbation of OCD symptoms are candidates for evaluation of possible infectious etiologies
4. Longitudinal cohort studies, particularly the largest one to date from Europe with results just released, indicate there is no indication for a role of new GAS exposures in relation to exacerbations of tic disorders. 5. More investigation is certainly needed…..
Stay tuned!
top related